Emerging Role of Belzutifan Combinations in Advanced Renal Cell Carcinoma

In this segment on advanced renal cell carcinoma, Dr. McGregor introduces emerging data from the LITESPARK-011 study evaluating belzutifan in combination with lenvatinib compared with cabozantinib in previously treated patients. Dr. Wulff and Dr. Geynisman discuss how they are interpreting these findings in the context of current clinical practice, noting that while the data are promising, they are not yet incorporated into NCCN recommendations. The panel highlights the novelty of targeting the HIF-2α pathway and the potential for this mechanism to expand treatment options beyond traditional VEGF-directed therapies. They also consider how efficacy signals, response rates, and safety profiles including anemia and hypoxia may influence adoption. The discussion reflects cautious optimism, emphasizing the need for longer-term data and regulatory guidance before widespread integration. Overall, the conversation underscores how emerging therapies may reshape sequencing strategies in advanced renal cell carcinoma in the near future.